Mechanistic PK/PD Modeling in Pediatrics
by
Toufigh Gordi, PhD
President, PK/PD and Clinical Pharmacology Services
Rosa & Co. LLC
May 22, 2012
1:00 - 2:00 pm EDT
I will present PK and system pharmacology models developed for the secondary
bile acid ursodiol in neonates . The utility of both models in describing
the data as well as the observed variability in neonates will be discussed.
Furthermore, I will also touch upon the use of Accelerated Mass Spectrometry
(AMS) in neonates studies.
The purpose of the ³Impact² series is to foster the use of M&S activities in
all phases of drug development by illustrating the advantages and enhancing
the applicability of M&S in product discovery, development, and marketing
programs. The series is intended for drug development project team members
from discovery to phase 4 clinical trials. This includes pharmacologists,
ADME scientists, PK/PD modelers, clinical pharmacologists, clinical
development team members, regulatory affairs specialists, and other
interested professionals.
Register for this free webinar at www.rosaandco.com/webinar
http://www.rosaandco.com/webinar . After registering you will receive a
confirmation email containing information about joining the webinar. More
information about the webinar series, an archive of past webinars, and a
list of future webinar speakers may be found at www.rosaandco.com/webinar
http://www.rosaandco.com/webinar .
Please allow 5-10 minutes for a Java applet to be installed on your computer
prior to joining our webinar series for the first time.
Toufigh Gordi, PhD
President, PK/PD and Clinical Pharmacology Services
Rosa & Co. LLC: www.rosaandco.com http://www.tgordi.com/
E-mail: [email protected] <mailto:[email protected]>
Tel.: 408-480-7314
Fax: 408-370-9810